CTI Clinical Trial and Consulting Services (CTI) has entered a collaboration with Galectin Therapeutics for a Phase I trial that will support a potential indication of GR-MD-02 for the treatment of non-alcoholic steatohepatitis (NASH or fatty liver disease) with advanced fibrosis.
 
The Phase I, multi-center, partially blinded, dose escalation trial will evaluate the safety of GR-MD-02 in subjects with Non-Alcoholic Steatohepatitis (NASH) with Advanced Hepatic Fibrosis, and will be conducted in six centers in the U.S.
 
“CTI is excited to be a part of such a groundbreaking clinical trial that will help a significant and progressive unmet medical need,” said Lynn Fallon, executive vice president and president, Consulting at CTI. “NASH affects between 9 and 15 million people in the U.S., and is the third leading indication for liver transplantation. This trial will be critical to helping patients where there is currently no approved medical therapy. CTI has extensive experience in liver disease, fibrosis, and in conducting first-in-human trials.”